Does the media favor OGN or ELAN?

In the previous week, Organon & Co. had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Organon & Co. and 6 mentions for Elanco Animal Health. Organon & Co.'s average media sentiment score of 1.24 beat Elanco Animal Health's score of 1.05 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OGN or CORT?

In the previous week, Organon & Co. had 5 more articles in the media than Corcept Therapeutics. MarketBeat recorded 9 mentions for Organon & Co. and 4 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.77 beat Organon & Co.'s score of 1.24 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer OGN or AXSM?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Organon & Co.. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.24 beat Axsome Therapeutics' score of 1.15 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OGN or RDY?

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 16.45%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor OGN or RDY?

In the previous week, Organon & Co. had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Organon & Co. and 3 mentions for Dr. Reddy's Laboratories. Organon & Co.'s average media sentiment score of 1.24 beat Dr. Reddy's Laboratories' score of 0.86 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRNX or OGN?

In the previous week, Organon & Co. had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 9 mentions for Organon & Co. and 4 mentions for Crinetics Pharmaceuticals. Organon & Co.'s average media sentiment score of 1.24 beat Crinetics Pharmaceuticals' score of 1.17 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Organon & Co. (OGN) Competitors

$13.64 +0.02 (+0.11%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$13.64 -0.01 (-0.07%)

As of 09/11/2026 07:30 PM Eastern

Compare

OGN vs. ELAN, CORT, AXSM, RDY, and CRNX

Should you buy Organon & Co. stock or one of its competitors? Organon & Co.'s main competitors and comparable companies include Elanco Animal Health (ELAN), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organon & Co. compare to Elanco Animal Health?

Organon & Co. (NYSE:OGN) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Organon & Co. has a net margin of 3.41% compared to Elanco Animal Health's net margin of -3.96%. Organon & Co.'s return on equity of 88.97% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Elanco Animal Health	-3.96%	8.13%	3.99%

Organon & Co. has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.72
Elanco Animal Health	$5.02B	2.31	-$232M	-$0.41	N/A

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 16.45%. Elanco Animal Health has a consensus target price of $29.09, suggesting a potential upside of 25.42%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Organon & Co. had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 9 mentions for Organon & Co. and 6 mentions for Elanco Animal Health. Organon & Co.'s average media sentiment score of 1.24 beat Elanco Animal Health's score of 1.05 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Organon & Co. beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Corcept Therapeutics?

Organon & Co. (NYSE:OGN) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 16.45%. Corcept Therapeutics has a consensus price target of $138.17, suggesting a potential upside of 22.50%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Organon & Co. has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

In the previous week, Organon & Co. had 5 more articles in the media than Corcept Therapeutics. MarketBeat recorded 9 mentions for Organon & Co. and 4 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.77 beat Organon & Co.'s score of 1.24 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Organon & Co. has higher revenue and earnings than Corcept Therapeutics. Organon & Co. is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.72
Corcept Therapeutics	$761.41M	16.01	$99.65M	$0.42	268.55

Corcept Therapeutics has a net margin of 6.52% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Corcept Therapeutics	6.52%	8.26%	6.45%

Summary

Corcept Therapeutics beats Organon & Co. on 10 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Organon & Co. (NYSE:OGN) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 2 more articles in the media than Organon & Co.. MarketBeat recorded 11 mentions for Axsome Therapeutics and 9 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.24 beat Axsome Therapeutics' score of 1.15 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.72
Axsome Therapeutics	$638.50M	18.11	-$183.17M	-$3.75	N/A

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 16.45%. Axsome Therapeutics has a consensus target price of $267.60, suggesting a potential upside of 21.22%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Organon & Co. has a net margin of 3.41% compared to Axsome Therapeutics' net margin of -24.68%. Organon & Co.'s return on equity of 88.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Organon & Co. has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

Summary

Organon & Co. beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

In the previous week, Organon & Co. had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for Organon & Co. and 3 mentions for Dr. Reddy's Laboratories. Organon & Co.'s average media sentiment score of 1.24 beat Dr. Reddy's Laboratories' score of 0.86 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 16.45%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Organon & Co. pays out 10.4% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Organon & Co. has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.72
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	27.06

Summary

Organon & Co. beats Dr. Reddy's Laboratories on 11 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Organon & Co. (NYSE:OGN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, suggesting a potential downside of 4.65%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 16.45%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Organon & Co. had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 9 mentions for Organon & Co. and 4 mentions for Crinetics Pharmaceuticals. Organon & Co.'s average media sentiment score of 1.24 beat Crinetics Pharmaceuticals' score of 1.17 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.72

Organon & Co. has a net margin of 3.41% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Organon & Co.'s return on equity of 88.97% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Organon & Co.	3.41%	88.97%	6.03%

Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Summary

Organon & Co. beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.58B	$12.46B	$7.17B	$23.20B
Dividend Yield	0.59%	2.62%	2.56%	3.56%
P/E Ratio	17.72	797.19	273.82	28.71
Price / Sales	0.58	760.88	656.53	94.63
Price / Cash	2.35	89.25	77.04	33.82
Price / Book	4.72	10.39	10.33	4.74
Net Income	$187M	$2.84B	$3.50B	$1.07B
7 Day Performance	-0.98%	-3.68%	-3.33%	-2.00%
1 Month Performance	-0.11%	0.80%	-0.42%	-2.68%
1 Year Performance	28.12%	3.48%	19.21%	10.45%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	1.5886 of 5 stars	$13.65 +0.1%	$11.40 -16.5%	+28.0%	$3.58B	$6.13B	17.72	10,000
ELAN Elanco Animal Health	4.3669 of 5 stars	$24.48 -0.1%	$29.09 +18.8%	+23.4%	$12.24B	$4.72B	N/A	9,400	Positive News
CORT Corcept Therapeutics	4.1781 of 5 stars	$111.62 flat	$138.17 +23.8%	+51.7%	$12.07B	$761.41M	265.77	300	Positive News Analyst Downgrade
AXSM Axsome Therapeutics	3.7956 of 5 stars	$206.68 flat	$267.60 +29.5%	+79.5%	$10.83B	$638.50M	N/A	380	Positive News
RDY Dr. Reddy's Laboratories	1.5958 of 5 stars	$11.97 flat	N/A	-19.1%	$9.99B	$3.58B	27.21	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. ELAN, CORT, AXSM, RDY, and CRNX

How does Organon & Co. compare to Elanco Animal Health?

Summary

How does Organon & Co. compare to Corcept Therapeutics?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Summary

How does Organon & Co. compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. ELAN, CORT, AXSM, RDY, and CRNX

How does Organon & Co. compare to Elanco Animal Health?

Is OGN or ELAN more profitable?

Which has more volatility and risk, OGN or ELAN?

Which has better valuation and earnings, OGN or ELAN?

Do analysts prefer OGN or ELAN?

Does the media favor OGN or ELAN?

Do insiders and institutionals hold more shares of OGN or ELAN?

Summary

How does Organon & Co. compare to Corcept Therapeutics?

Do insiders & institutionals have more ownership in OGN or CORT?

Do analysts recommend OGN or CORT?

Which has more risk and volatility, OGN or CORT?

Does the media refer more to OGN or CORT?

Which has preferable valuation & earnings, OGN or CORT?

Is OGN or CORT more profitable?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Do institutionals and insiders have more ownership in OGN or AXSM?

Does the media prefer OGN or AXSM?

Which has better earnings and valuation, OGN or AXSM?

Do analysts recommend OGN or AXSM?

Is OGN or AXSM more profitable?

Which has more risk & volatility, OGN or AXSM?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Does the media favor OGN or RDY?

Do institutionals and insiders hold more shares of OGN or RDY?

Is OGN or RDY more profitable?

Do analysts recommend OGN or RDY?

Is OGN or RDY a better dividend stock?

Which has more volatility & risk, OGN or RDY?

Which has stronger valuation & earnings, OGN or RDY?

Summary

How does Organon & Co. compare to Crinetics Pharmaceuticals?

Do analysts recommend CRNX or OGN?

Does the media prefer CRNX or OGN?

Do insiders and institutionals hold more shares of CRNX or OGN?

Which has stronger earnings and valuation, CRNX or OGN?

Is CRNX or OGN more profitable?

Which has more risk & volatility, CRNX or OGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools